ACTC moving ahead with Phase 1/2 trials

Good news for ACTC, the trial is now half over and will be finished in 2013. That news got ACTC over 6 cents to close at 0.061 on 9.6 million shares. The three month avg. is 6.6 million shares. ................................................................... ....................................................................................... Welcome to my nightmare, after I sold most of my Geron shares [at around $1.35] it's up and closed at $1.70. Yea if it wasn't for bad luck I'd have no luck at all....... ............................................................................................................................................................................. AAPL I think is done going down, the last time I said that it went down 30 more point. AAPL closed at $518.83 up $9.04 ON 26.9 MILLION SHARES. The three month avg. is 21.4 million shares. ..................................................................... ................................................................................................................................................................................Good luck in this rigged casino,

Geron up again

Will Geron was up 3 days in a row, good sign, it closed at $1.42 up 3 cents, on 2+ million shares. The three month avg. is 1.2 million shares. ........................... ................................................................................................................................................................................ACTC still going down slowly closed at 0.055, on 5.2 million shares. The three month aavg. volume is 6.5 million shares.................................................... ............................................................................................................................................................................. BTX closed down 6 cent at $3.42 on only 36,571 shares. The three month avg. volume is 90,552 shares. ....................................................................... ...............................................................................................................................................................................AAPL down $2.39 at $539.00. AAPL should be going up, with Apple TV coming[maybe] and China buying all those iPhone......................................................... Good luck in this rigged casino,

Geron up

Geron went up 17 more cents to close at $1.39 on 3.7 million shares. The three month avg. is 1.3 million. The avg days up for most stocks is three days, then a little pull back and then if the move is real the stock will go up again, if not down. This is the 3rd day, lets see what happens......................................................... ....................................................................................... ....................................................................................... .....................................................................................................................................................................................................................................................................ACTC just keeps going down may add a few shares under 5 cents........................ .............................................................................................................................................................................................................................................................................................................................................................BTX I started a postion with 100 shares. I feel they may be the next big thing. I thought that about Geron and lost my ass.............................................. ....................................................................................... ....................................................................................... .....................................................................................................................................................................................................................................................................AAPL looks like it's done going down closed at $541.39 up $11.57 on normal volume... ...........................................................................................................................................................................................Good luck in this rigged casino,

Geron up 15%

Geron closed up 16 cents at $1.22 on 6+ million shares. The three month avg. is 1.5 million shares. I sold all but 1,700 shares. Geron in the past never holds the gains for long. Lets see if it holds Monday's gains.......................................... .............................................................................................................................................................................. ACTC down under 6 cent, we go lower with no good news, no reverse split and no partner. ...................................................................................................................................................................................BTX was up 16 cents to close at $3.44, had a order in, but didn't hit my price. If BTX gets Geron's stem cell property, I'm going to change title of blog to BioTime the furture in bio tech. I checked there website and they are in it big time with seven different companies. The problem, they all are losing money...................... .............................................................................................................................................................................. Good luck in this rigged casino,

Geron Positive Results from Phase 2 Study of Imetelstat

MENLO PARK, Calif., December 10, 2012 - Geron Corporation (GERN) today announced positive clinical results from the Phase 2 trial of imetelstat, the company`s first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET). ET is a chronic blood disorder that is representative of a group of diseases known as myeloproliferative neoplasms (MPNs). The data, which showed rapid and durable hematologic and molecular responses in patients treated with imetelstat, were presented Sunday evening in an oral session at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, by Prof. Dr. med. Gabriela M. Baerlocher of the University Hospital and University of Bern, Switzerland, and a principal investigator of the trial. To view the presentation slides, please visit www.geron.com/PDFs/Geron-Imetelstat-ETPh2-ASH-2012.pdf. .............................. ...............................................................................................................................................................................I sold most of my shares in Geron, will put most of the money in IBB and DVY. Geron is up 29% at $1.37. The results are good but it will take 2-3 years at least to bring to market, and the market for ET is small. Also I don't believe in Geron management. Plus I'm old and will be retiring soon, need income and stable share price. ........... ...............................................................................................................................................................................Good like in this rigged casino,

Geron is a Train Wreck

Shares fell 20% when it gave up on development of treatments using stem cells last year and an additional 56% earlier this year when its lead cancer drug, imetelstat, failed a phase 2 trial in breast cancer. And now it's down 25% today after disclosing that its (now lead) drug GRN1005 failed to show an effect on brain metastases in patients with breast cancer. What's left? Imetelstat. While it was hit by an oncoming train, it appears the drug wasn't completely knocked off the track. Geron blamed the lack of success in breast cancer patients on overlapping toxicities of imetelstat and a chemotherapy it was combined with, which led doctors to decrease the chemotherapy dose. The biotech also stopped a lung cancer trial where imetelstat was used as a single agent because it appeared that any effect Geron might see wouldn't be statistically significant. As it had planned to do after the trial ended, Geron looked at patients with tumors that had short telomeres -- the protective ends of chromosomes -- and found patients in that subgroup taking imetelstat progressed slower than those on placebo. The data are only from 19 patients, but the finding makes sense scientifically. Imetelstat is designed to inhibit the enzyme responsible for lengthening telomeres. Giving the drug a head start by starting with short telomeres would make it easier for the drug to kill the tumor cell. Geron also has data from a phase 2 trial in patients with essential thrombocythemia, a blood cancer, where 100% of the patients had a response with 13 out of the 14 patients achieving a complete response. These are patients that failed or couldn't take other therapies, so any response is pretty impressive. .............................................................................................................................................................................. That was from Motley Fool's website.................................................... Geron hit a new low of .91 and closed at $1.14 on 6+ million shares. The three month avg. is 1.5 million shares........................................................... ........................................................................................My Wife was so upset, she sold all her Geron shares at market, for 94 cents a shares. Told me when the money clears, close the IRA account, take all the money out. If I don't stop losing money by 2014, I'm going to do the same thing. The average investor doesn't stand a chance. It's a rigged casino. I can make more money buying junk and reselling it, which I enjoy doing.

Geron unbelievable 1 out of 6 trials postive

MENLO PARK, Calif., December 3, 2012 - Geron Corporation (GERN) today announced that the company has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres. The company also announced a restructuring to reduce its workforce from 107 positions to 64 full-time positions, and to reduce its annual cash operating expenses from approximately $65 million in 2012 to approximately $33 million in 2013, which includes non-recurring costs of approximately $3 million associated with the restructuring and approximately $3 million for the discontinuation of clinical trials. The company expects to end 2012 with approximately $90 million in cash and investments................................. ....................................................................................... Only one phase 2 trial out of six has positve results. The one trial of Imetelstat it's drug to treat essential thrombocytosis [ET] and certain types of tumors............... ...................................................................................... Geron was down over 20% afterhours. Will start selling a little each week after Dec 9th when Chip will say a few more words about his plans for Geron...................... This is a disaster..................................................................... ......................................................................................................................................................................................................................................................................Good luck in this rigged casino,